SER130 Composition of Matter patent opposition period expires
Oslo, Norway – November 7, 2017 – Serodus ASA yesterday received a notice from the European Patent Office that the opposition period (a nine months period post-grant of the patent) expired for the SER130 Composition of Matter patent granted to University of Copenhagen and licensed to Serodus 16 December 2008, and no opposition to the patent was filed.
The patent, entitled "IL-4-derived peptides for modulation of the chronic inflammatory response and treatment of autoimmune diseases (European patent EP 2365983) covers SER130 in treatment of various diseases caused by inflammation. Pre-clinical studies have demonstrated that SER130 is an effective anti-inflammatory peptide. SER130 stimulates the body’s own anti-inflammatory preparedness. Pre-clinical studies have demonstrated that SER130 is safe and well tolerated and the compound is ready to enter the clinical development phase.
Serodus’ CEO, Eva Steiness said "It is very important that the patent on SER130 in Europe is in place. Serodus will continue the development of SER130 for treatment of Acute Myocardial Infarction, a leading cause of cardio-vascular death in the Western World”.
About Serodus ASA
Serodus is a private Scandinavian biotech company focusing on novel, immuno-modulators halting progression of diabetic comorbidities, such as diabetic kidney disease (diabetic nephropathy).
The pipeline consists of five programs; two of which are in clinical development, two are at the pre-clinical stages and one in the exploratory stage. Our immune-modulatory pipeline candidates have different target-based actions, i.e. (1) SER150 is the most clinically advanced and addresses diabetic nephropathy. SER150 is an oral treatment with dual mode of action that both inhibits thromboxane synthase and blocks the thromboxane receptor, (2) SER130, an IL-4 peptide agonist for treatment of Acute Myocardial Infarction, (3) SER140, an IL-1 peptide antagonist for treatment of Type 2 diabetes, (4) SER190, an IL-1 peptide antagonist for treatment of diabetic foot ulcer and (5) SER190, an Aquaporin 1 (ORL-1) modulator receptor agonist for treatment of Pulmonary Arterial Hypertension. This compound has received an Orphan Drug Designation in the US.